Regular Research Article

Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial

Areoo Samaei, Kamyar Moradi, Sayna Bagheri, Amir Ashraf-Ganjouei, Rosa Alikhani, Seiedeh Bentolhoda Mousavi, Farzin Rezaei, Shahin Akhondzadeh

Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran (Drs Samaei, Moradi, Bagheri, Ashraf-Ganjouei, and Akhondzadeh); Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran (Drs Alikhani and Mousavi); Qods Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran (Dr Rezaei).

A.S. and K.M. contributed equally to this study.

Correspondence: Shahin Akhondzadeh, PhD, Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, Iran 13337 (s.akhond@neda.net).

Abstract

Background: Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia.

Methods: In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms.

Results: A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = .180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P < .001; F = 5.42, df = 1.56, P = .011; F = 7.64, df = 1.48, P = .003). HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups.

Conclusion: Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms.

Keywords: clinical trial, primary negative symptoms, resveratrol, schizophrenia
Significance Statement
Schizophrenia is a prevalent, complex mental health disorder affecting neuropsychological domains. Schizophrenia patients can present negative symptoms such as loss of functional, verbal, and social abilities, which are usually complex in nature and resistant to conventional therapies. Hence, it is of great importance to use supplementary medications in addition to FDA-approved reagents to suppress negative symptoms as well. In this regard, we designed a randomized, double-blinded, placebo-controlled, parallel-group clinical trial and investigated the efficacy and safety of resveratrol add-on to risperidone. Notably, resveratrol has been recognized as a natural nonflavonoid polyphenol with antioxidative, antipoptotic, antiinflammatory, and neuroprotective characteristics. As hypothesized, we identified the beneficial effects of resveratrol adjunct therapy on primary negative symptoms without any significant change in terms of safety in patients with stable schizophrenia. To the best of our knowledge, this study provides novel evidence regarding the beneficial roles of resveratrol supplementation in negative symptom treatment.

Introduction
Schizophrenia is a complex, chronic mental health disorder causing a cascade of self-care, occupational, and cognitive impairments. The estimated prevalence of schizophrenia is 4.6–7.2 per 1000 individuals; meanwhile, it accounts for a remarkable portion of debility and costs among mental illnesses throughout the world (Saha et al., 2005; Rezaei et al., 2017; Hastrup et al., 2020). Schizophrenia can present a variety of neuropsychological disabilities, of which negative symptoms tend to be chronic and extremely debilitating, characterized by loss of various functions such as facial and emotional expressions, social communications, and verbal output (Akhondzadeh, 2001; Mitra et al., 2016). Despite the noticeable efficacy of the current antipsychotics in different perspectives of schizophrenia, the treatment of negative symptoms still remains challenging due to the complex nature and pathophysiology (Kirkpatrick et al., 2006; Chue and Lalonde, 2014; Millan et al., 2014).

A large body of evidence has reported the importance of cytokine disruption and propensity for the production of proinflammatory cytokines in schizophrenia that give rise to imbalance between neuroprotective and neurodegenerative factors (Potvin et al., 2008; Miller et al., 2011; Mansur et al., 2012; Upthegrove et al., 2014). In agreement, there is convincing evidence regarding the implication of dysregulated inflammatory pathways in negative symptoms (Kirkpatrick and Miller, 2013). Interestingly, oxidative stress that is intimately linked to a variety of pathophysiological processes, such as inflammation, has been proposed to contribute to the etiology of schizophrenia (Bitan-Nihrwe and Woo, 2011). Another underlying mechanism predisposing schizophrenic patients to develop negative symptoms might be the alteration in action mechanisms of different neurotransmitters, including glutamate, dopamine, GABA, acetycholine, and serotonin (Carlsson et al., 1999; da Silva Alves et al., 2008; Howes and Kapur, 2009; Brisch et al., 2014; Ghajar et al., 2018b).

On the other hand, nutritional supplements are of great interest in neuropsychiatric disorders (Ghajar et al., 2017, 2018b). Resveratrol (3,5,4′-trihydroxystilbene) is a natural nonflavonoid polyphenol that can be found in the skin of red grapes, red wine, and other natural dietary sources such as peanuts (Saiko et al., 2008). Resveratrol has wide beneficial effects, including antioxidative, antipoptotic, antiinflammatory as well as neuroprotective effects (Khanhasamy et al., 2011). Resveratrol crosses the blood brain barrier due to its lipophilic characteristic (Rege et al., 2014) and can play a considerable role in preventing neuroinflammation and oxidation in the brain (Jeon et al., 2012b; Rege et al., 2013; Pineda-Ramirez et al., 2018). Moreover, resveratrol can generate neurotrophic factors by prompting astroglial cells, leading to the revival of disrupted dopaminergic neurons (Zhang et al., 2012). Altogether, it appears that resveratrol might positively affect schizophrenia patients and improve their symptoms, especially negative symptoms.

There is growing evidence regarding the use of resveratrol in many neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s disease as it could exert neuroprotective effects against brain damage induced by toxins and inflammation (Jeon et al., 2012a; Rege et al., 2013; Giovinazzo and Greco, 2015; Pasinetti et al., 2015). Beyond the common use, a number of previous double-blind, placebo-controlled, interventional studies in healthy adults have recommended a beneficial role for resveratrol in the treatment of cognition and memory impairment (Kennedy et al., 2010; Witte et al., 2014). Taken together, we assumed that resveratrol might be capable of improving negative symptoms. In this regard, we aimed to evaluate the efficacy and safety of resveratrol adjunct therapy in the management of negative schizophrenia-related symptoms in a double-blind, placebo-controlled setting for 8 weeks.

Methods
Study Design and Setting
An 8-week, randomized, double-blinded, placebo-controlled, parallel-group trial was conducted on patients with chronic stable schizophrenia at general psychiatric clinics, Roozbeh Psychiatric Hospital and Razi Psychiatric Hospital, from January 2018 to March 2019. After a complete description of the trial and its purpose, written informed consent was obtained from patients and their legally authorized representatives. They were notified of their right to withdraw from the trial at any time. The institutional review board of Tehran University of Medical Sciences approved the trial protocol (IR.TUMS.VCR.REC.1396.4183) that had been defined in full accordance with the latest version of Declaration of Helsinki (Declaration of Helsinki, as revised in Brazil 2013). The trial was registered in the Iranian registry of clinical trials (http://www.irct.ir; registration no.: IRCT20090117001556N103).

Participants
Eligible participants (n=60) were patients with 18–60 years of age who met the diagnostic criteria for chronic schizophrenia based on the fifth edition of Diagnostic and Statistical Manual of Mental Disorders and a minimum disease duration of 2 years (based on the Structured Clinical Interview for Diagnostic and Statistical Manual-5 Clinical Version (2013). In addition, participants must have had a minimum score of 15 in negative...
sub-score of positive and negative syndrome scale (PANSS) as well as clinical stability on a stable dose of risperidone for the last 8 weeks prior to the beginning of the study. Clinical stability was delineated as ≤20% change in the total score of PANSS on 2 consecutive ratings (every 2 weeks for a month) (Kay et al., 1987). Patients who have demonstrated any serious medical or neurological problem were excluded. Other exclusion criteria were intellectual disability based on clinical judgement of intelligence quotient <70, alcohol or substance dependence during the last 6 months (except for nicotine and caffeine), suicide ideation, a score of 14 or above on the Hamilton Depression Rating Scale (HDRS), a score of ≥2 on the suicide item of HDRS, receiving electroconvulsive therapy during the last 3 months, lactation, pregnancy, history of allergy to risperidone or reseratrol, history of neurosurgery, or history of head trauma.

Intervention

Eligible participants were randomly assigned to receive either risperidone (Risperdal, Janssen Pharmaceuticals, 4–6 mg) combined with reseratrol (ACER, Tehran, Iran; 200 mg/d) or risperidone (4–6 mg) combined with matched placebo capsule with an allocation ratio of 1. The dose selection for reseratrol was according to previous studies showing that high doses of the reagent may contribute to inhibition of cytochrome P450 isoenzymes and therefore, drug-drug interactions (Detampel et al., 2012). The medication regimen of participants was tightly controlled, since they were not allowed to use additional antipsychotics, second antipsychotic agents, or mood stabilizers. Adherence to the medication plan was evaluated by comparing weekly the number of consumed capsules considering the report of medication intake from participants.

Outcome

Schizophrenia-related psychopathological symptoms of participants were assessed using PANSS at baseline and at weeks 2, 4, 6, and 8 of the trial period. PANSS is a validated rating scale composed of 30 items that can be employed to measure positive (7 items), negative (7 items), and general (16 items) pathological symptoms of schizophrenia (Kay et al., 1987). In addition, the 17-item HDRS was used at baseline and week 8 to quantify depressive symptoms and their changes over the trial period (Hamilton, 1960). Both scales have been widely employed in previous clinical trials of schizophrenia in the Iranian population (Iranpour et al., 2016; Rezaei et al., 2017; Ghajar et al., 2018a).

The primary outcome of interest in the present study was defined as differences in PANSS negative subscale score reduction from baseline to week 8 between the treatment groups. Secondary outcome measures were considered as changes in other PANSS sub-scores between the treatment arms during 8 weeks of study.

Safety

Extrapyramidal symptom rating scale (ESRS; part one: parkinsonism, dystonia, dyskinesia; sum of 11 items) was administered at baseline and at weeks 1, 2, 4, 6, and 8 to assess the extrapyramidal complications. ESRS can measure all drug-induced movement disorders irrespective of changes in psychopathology as measured by the PANSS (Chouinard and Margolese, 2005). The ESRS was previously applied in Iranian clinical trials demonstrating valid results (Iranpour et al., 2016; Rezaei et al., 2017; Ghajar et al., 2018a).

All eligible participants underwent thorough physical examination, 12-lead electrocardiography, complete blood counts, and liver function tests at baseline. Additionally, vital signs and body weight of each participant were monitored at each visit. Patients were educated to inform the research coordinates in case of any unexpected symptoms during the trial period. In addition to assessing extrapyramidal complications by ESRS, all cases were systematically asked whether they struggled with any kind of adverse effect during the trial, using open-ended questions followed by a 25-item checklist of side effects (Khajavi et al., 2012; Shahmansouri et al., 2014).

Sample Size

The minimal sample size of 44 (22 in each group) was calculated based on assumption of a clinically significant difference of 3 on the PANSS negative subscale score, a SD of 3, a 2-tailed significance of 0.05, and a power of 90%. Considering a dropout rate of 20%, 54 participants were required. We enrolled 60 patients in the trial (30 in each group).

Randomization, Allocation Concealment, and Blinding

Participants were randomly assigned to the treatment arms in a 1:1 ratio using a computer-generated code. The allocated group number was kept confidential in sealed opaque envelopes until data analysis. Resveratrol and matched placebo were identically encapsulated in terms of size, shape, color, and smell. Randomization, allocation, and blinding procedures were performed by an independent group not involved elsewhere in the study. Participants, outcome raters, medication distributor, referring physician, and research team were all blinded to the assignments.

Statistical Analysis

Statistical analysis was carried out using the Statistical Package of Social Science Software (SPSS, version 24, IBM Company, Armonk, NY) for Windows. Graphs related to outcomes of interest were drawn using the GraphPad Prism 7 software (San Diego, CA). Compliance of variables with normal distribution was examined with the Shapiro-Wilk test and probability graphics. P values <.05 were considered statistically significant in data analyses. Categorical variables were reported in percentages (%) while continuous data were represented as mean ± SD. Baseline variables were compared between the groups using an independent t test with Levene’s test for equality of variance. The general linear model repeated-measures ANOVA analysis (corrected by Greenhouse–Geisser test in nonspherical cases) was used to compare scores of the PANSS, including of positive, negative, general, and total subsections, as well as ESRS score between the treatment arms over the course of the study. In addition, the quantity of the change in the PANSS scores from baseline to week 8 was measured using an independent t test with Levene’s test for equality of variance. Finally, the Fisher’s exact test was utilized to collate the frequency of side effects between the applied treatment strategies.

Results

Baseline Characteristics of the Patients

Of 98 patients screened for eligibility, 60 patients were enrolled and randomly assigned to receive either risperidone plus reseratrol (n=30) or risperidone plus placebo (n=30) (Figure 1). Fifty-two
participants completed the trial and underwent statistical analysis since 4 participants from each arm withdrew from the trial before the second week. Baseline positive, negative, general psychopathology, and total PANSS symptom scores, in addition to HDRS and ESRS values, were not significantly different between the 2 groups. The detailed description of baseline data is shown in Table 1. Participants showed favorable adherence to their treatment strategies.

**Negative Symptoms**

Repeated-measure analysis of ANOVA demonstrated significant effect of time (Greenhouse-Geisser corrected: $F = 212.27$, $df = 2.04$, $P < .001$) and time-treatment interaction (Greenhouse-Geisser corrected: $F = 12.25$, $df = 2.04$, $P < .001$), suggesting that the treatment groups had different behavior across time (Figure 2A).

Table 2 gives a full image of reduction rates from baseline at measurement points for both arms. By week 8, the reduction rate from baseline score was significantly greater in the resveratrol group compared with the placebo group (MD [95% CI] = −2.38 [−3.67, −1.1], $df = 50$, $t = −3.73$, $P < .001$).

**Positive Symptoms**

Repeated-measure analysis indicated significant effect of time (Greenhouse-Geisser corrected: $F = 334.72$, $df = 1.88$, $P < .001$). Nevertheless, the effect of time-treatment interaction was not significant (Greenhouse-Geisser corrected: $F = 1.76$, $df = 1.88$, $P = .180$), proposing similar changing trends of the groups in terms of positive symptoms (Figure 2B).

**General Psychopathology**

Repeated-measure analysis exhibited significant effect of time (Greenhouse-Geisser corrected: $F = 365.98$, $df = 1.56$, $P < .001$). The effect of time-treatment interaction was also significant over the trial period (Greenhouse-Geisser corrected: $F = 5.42$, $df = 1.56$, $P = .011$), showing the differing influence of the treatment strategies on general psychopathology across time (Figure 2C). At week 8 of the study, the reduction rate from baseline score was significantly greater following resveratrol add-on to risperidone compared with the placebo adjunctive therapy (MD [95% CI] = −2.42 [−4.22, −0.62], $df = 37.58$, $t = −2.72$, $P = .010$).

**PANSS Total Score**

The general linear model analysis of ANOVA was representative of differing efficacy of the administered treatment schedules over time, since it showed significant effect of time-treatment interaction (Greenhouse-Geisser corrected: $F = 448.81$, $df = 1.48$, $P < .001$) in addition to significance of time effect (Greenhouse-Geisser corrected: $F = 7.64$, $df = 1.48$, $P = .003$) (Figure 2D). At the end of the trial, the reduction rate from baseline score was significantly greater following resveratrol add-on to risperidone compared with the placebo adjunctive therapy (MD [95% CI] = −2.38 [−3.67, −1.1], $df = 50$, $t = −3.73$, $P < .001$).

### Table 1. Baseline Characteristics of the Patients

| Variable                  | Resveratrol (n = 26) | Placebo (n = 26) |
|---------------------------|----------------------|------------------|
| Gender, F(%)              | 10 (38%)             | 11 (42%)        |
| Age, mean ± SD            | 34.73 ± 7.03         | 33.08 ± 5.48    |
| Duration of illness, y, mean ± SD | 11.46 ± 6.43       | 10.65 ± 5.20   |
| Schizophrenia subtype     |                      |                  |
| Paranoid (%)              | 16 (61%)             | 17 (69%)        |
| Residual (%)              | 4 (15%)              | 5 (19%)         |
| Undifferentiated (%)      | 6 (23%)              | 5 (19%)         |
| Marital status            |                      |                  |
| Single                    | 16 (61%)             | 18 (69%)        |
| Married                   | 7 (27%)              | 5 (19%)         |
| Divorced                  | 3 (11%)              | 3 (11%)         |
| Level of education        |                      |                  |
| Less than high school     | 19 (73%)             | 17 (69%)        |
| diploma                   | 4 (15%)              | diploma: 7 (27%), |
| illiterate                | 3 (11%)              | illiterate: 2 (7%) |
| Smoking                   | 22 (84%)             | 23 (88%)        |
| Baseline HDRS score, mean ± SD | 9.84 ± 1.97         | 10.15 ± 1.97    |
| Baseline ESRS, mean ± SD  | 0.77 ± 0.99          | 0.38 ± 0.70     |
| Baseline PANSS             |                      |                  |
| Total score               | 70.08 ± 5.11         | 70.27 ± 4.21    |
| Negative symptoms         | 17.69 ± 2.53         | 18.04 ± 1.75    |
| Positive symptoms         | 20.58 ± 1.90         | 20.31 ± 2.17    |
| General psychopathology   | 31.81 ± 2.40         | 31.92 ± 1.74    |

Abbreviations: ESRS, extrapyramidal symptom rating scale; F, female; HDRS, Hamilton Depression Rating Scale; PANSS, positive and negative syndrome scale.
significantly greater following resveratrol add-on to risperidone compared with the placebo adjunctive therapy (MD [95% CI] = −6.00 [−10.00, −1.99] df = 50, t = −3.01, P = .004).

ESRS

Although the effect of time was significant based on 2-way repeated-measures analysis of ANOVA (Greenhouse-Geisser corrected: P* = 11.70, df = 3.11, P < .001), the groups showed no significantly different behavior across time, according to the analysis for the effect of time-treatment interaction (Greenhouse-Geisser corrected: P* = 0.94, df = 3.11, P = .424) (Figure 3).

Hamilton Depression Rating Scale

Similar to the baseline data, the treatment arms were not significantly different at the end of the trial (MD [95% CI] = −0.50 [−10.00, −1.99], df = 50, t = −1.07, P = .291), which is illustrative of statistically similar status of depressive symptoms between participants of the groups.

Adverse Events

The details of detected side effects were listed in Table 3. All of the adverse events were tolerable with mild to moderate severity. The most frequent side effects were increased appetite and constipation in both of the groups. The frequency of complications other than extrapyramidal symptoms did not differ significantly between the groups (P > .05).

Discussion

In this study, we demonstrated that adding resveratrol to the treatment regimen is well tolerated and improves negative symptoms of schizophrenia. Patients treated with resveratrol had significantly greater reduction of PANSS negative subscale from baseline, general psychopathology, and PANSS total score compared with the placebo group. Since negative symptoms can be affected by other manifestations such as positive and depressive symptoms, all patients were stabilized prior to the study to minimize the confounding factors. This claim is supported by the fact that baseline characteristics of both groups were not significantly different.

Management of negative symptoms is still a challenge for physicians because most antipsychotic agents do not have satisfactory effects on these symptoms (Erhart et al., 2006). Therefore, numerous studies have aimed to elucidate the pathophysiology behind negative symptoms, suggesting contribution to disruption in dopaminergic signaling pathways, GABAergic–glutamatergic balance, and inflammatory processes (Millan et al., 2014). In this regard, several clinical trials have been performed to investigate the beneficial role of adjunct therapies targeting these pathways. For instance, L-carnosine that is an antioxidant, significantly improved the negative score of schizophrenic patients (Ghajar et al., 2018b). In addition, Berk and colleagues demonstrated that adding N-acetyl cysteine to maintenance treatment of schizophrenia could significantly improve PANSS negative score (Berk et al., 2008). The combination...
As mentioned earlier, resveratrol is a phytoalexin compound that is found in various dietary sources, including grapes and peanuts, being known as an antiinflammatory, antioxidant, and neuro-protective agent. Since oxidative stress plays a prominent role in the pathogenesis of neurological diseases such as stroke and Alzheimer’s disease (AD), many researchers intended to evaluate its potential effects in these disorders. For instance, in patients with AD, treatment with resveratrol decreases the activity of matrix metalloproteinase-9, which is associated with the neurodegenerative process in AD patients (Turner et al., 2015). In this regard, resveratrol is proposed to decrease the activity of N-methyl-d-aspartate receptors and intracellular Ca2+, which has been associated with the severity of negative symptoms in schizophrenic patients (Chung et al., 2010; Pasinetti et al., 2015). Though the cellular and molecular aspects of adding resveratrol to the treatment regimen of schizophrenic patients were not evaluated in our study, these mechanisms could explain some of the observed improvements resulting from the add-on.

Moreover, it has been assumed that hypoactivity of the dopaminergic system (particularly in the prefrontal cortex) is associated with negative symptoms in schizophrenia (Remington et al., 2011). In this regard, brain-derived neurotrophic factor has been associated with dopamine release in the brain (Narita et al., 2003), and its level is negatively correlated with negative symptoms in patients with schizophrenia (Tan et al., 2005). Interestingly, resveratrol administration has been shown to have antidepressant effects in an animal model of depression via the activation of brain-derived neurotrophic factor (Hurley et al., 2014). Furthermore, it has been shown that resveratrol has protective effects against glutamate toxicity by alternating the activity of Na+-K+-ATPase and glutamine synthetase (Quincozes-santos et al., 2014). This would prevent the dysregulation of N-methyl-d-aspartate receptors and intracellular Ca2+, which has been associated with the severity of negative symptoms in schizophrenic patients (Coyle et al., 2003; Coyle and Tsai, 2004).

Considering the immunomodulatory effects of resveratrol, previous studies have indicated that it prevents the production of interleukin (IL)-12 and tumor necrosis factor alpha by macrophages in addition to decreasing the production of IL-12 and interferon-gamma by lymphocytes (Gao et al., 2001). Available evidence suggests that patients with schizophrenia have higher levels of inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor-alpha (Potvin et al., 2008). Moreover, the severity of negative symptoms is positively correlated with increased levels of IL-6, IL-8, and C-reactive protein (Meyer et al., 2011). Since neurotransmitter (such as dopamine) interaction with inflammatory cytokines is indicated in the pathophysiology of schizophrenia, the above-mentioned pathways could also justify the significant reduction of negative symptom severity in schizophrenic patients receiving resveratrol as supplement therapy.

Although this is the first study, to our knowledge, evaluating the efficacy and safety of resveratrol as an add-on to risperidone in patients with chronic schizophrenia, a few studies had investigated the effects of resveratrol in animal models of schizophrenia and patients with schizophrenia. Interestingly, in a study by Zortea and colleagues, treatment with a 200-mg/d supplement of resveratrol in patients with schizophrenia did not have any significant effect on cognitive performance (Zortea et al., 2016). Although their study was of great value, it had some limitations such as a small sample size and short period of follow-up (Zortea et al., 2016). Moreover, Magaji et al. demonstrated that administering 200- and 400-mg/kg doses of resveratrol have significant antipsychotic and anxiolytic effects in the murine model of anxiety and schizophrenia (Magaji et al., 2017), which is in line with our results.

| Measurement points | Resveratrol (n = 26) | Placebo (n = 26) | Paired differences |
|--------------------|----------------------|-----------------|--------------------|
|                   | Mean   | SD     | t      | P  | Mean   | SD     | t    | P   |
| Week 2            | 1.46   | 1.58   | 4.71   | .000 | 1.07   | 0.39   | 14.00 | .000 |
| Week 4            | 3.73   | 1.84   | 10.31  | .000 | 2.31   | 0.84   | 14.05 | .000 |
| Week 6            | 5.11   | 2.06   | 12.63  | .000 | 3.15   | 1.05   | 15.36 | .000 |
| Week 8            | 6.42   | 2.89   | 11.34  | .000 | 4.04   | 1.51   | 13.64 | .000 |

![Figure 3. Repeated-measure ANOVA for comparison of effects of 2 treatments on the ESSRS score. Values represent mean ± SEM.](https://academic.oup.com/ijnp/advance-article/doi/10.1093/ijnp/pyaa006/6015733)
Although the current study has several advantages such as being novel, placebo controlled, double blinded, and adjusted with consideration to baseline variables, some limitations should be considered. Our follow-up period was relatively short and the sample size was small. Furthermore, the measurement of serum/cerebrospinal fluid biomarkers or neurotransmitters was not performed in order to propose a more precise justification for the observed results.

In conclusion, this study provides robust evidence considering the beneficial role of adding resveratrol to risperidone in the management of negative symptoms in patients with chronic schizophrenia. Further studies could elucidate the underlying mechanisms of supplement therapies such as resveratrol.

Acknowledgments

This study was the postgraduate thesis of Dr Arezoo Samaei under the supervision of Prof. Shahin Akhondzadeh for the Iranian Board Psychiatry and supported by a grant from Tehran University of Medical Sciences (grant no.: 36431). The funding organization had no role in any part of the study.

Statement of Interest

The authors have declared that they have no conflicts of interest to disclose.

References

Akhondzadeh S (2001) The 5-HT hypothesis of schizophrenia. Idrugs 4:295–300.
Akhondzadeh S, Tabatabae M, Amini H, Ahmadi Abhari S, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179–185.
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Onding-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361–368.
Bitanihirwe BK, Woo TU (2011) Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 35:878–893.
Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, Bogerts B, Braun K, Braun AK, Jankowski Z, Kumaratiike J, Kumaratilake J, Henneberg M, Gos T (2014) The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 5:47.
Carlsson A, Waters N, Carlsson ML (1999) Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry 46:1388–1395.
Chen J, Bai Q, Zhao Z, Sui H, Xie X (2016) Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol Scand 134:54–60.
Chouinard G, Margolese HC (2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76:247–265.
Chue P, Lalonde JK (2014) Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat 10:777–789.
Chung S, Yao H, Cai X, Wang J, Arunachalam G, Rahman I (2010) Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501:79–90.
Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32–38.
Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318–327.
Cowan DS, Carpenter WT (2006) Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32:234–237.
Erhart SM, Marder SR, Carpenter WT (2006) Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32:234–237.
Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC (2001) Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 62:1299–1308.
Gharaj A, Neishabouri SM, Velayati N, Jahangard L, Matinnia N, Haghighi M, Ghaleiha A, Afarideh M, Salimi S, Meysamie A, Akhondzadeh S (2017) Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial. Pharmacopsychiatry 50:152–160.
Gharaj A, Gholamian F, Tabatabaei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S (2018a) Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Hum Psychopharmacol 33:e2662.
Gharaj A, Khoae-Ardakani MR, Shahmoradi Z, Alavi AR, Afarideh M, Shalbafan MR, Ghazizadeh-Hashemi M, Akhondzadeh S (2018b) L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Psychiatry Res 262:94–101.
Giovannozz G, Grecko F (2015) Functional properties of grape and wine polyphenols. Plant Foods Hum Nutr 70:454–462.
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
Hasstrup LH, Simonsen E, Ibsen R, Jellberg J, Jennum P (2020) Societal costs of schizophrenia in Denmark: a nationwide matched controlled study of patients and spouses before and after initial diagnosis. Schizophr Bull 46:68–77.
Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35:549–562.
Hurley LL, Akinfresoye L, Kalejaiey O, Tizabi Y (2014) Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res 268:1–7.
Irandour P, Zandifar A, Farokhnia M, Gougol A, Yekhezat H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeinoddini A, Mohammadjejad P, Zeinoddini A, Akhondzadeh S (2016) The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Hum Psychopharmacol 31:103–112.
Jeon BT, Jeong EJ, Shin HJ, Lee Y, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS (2012a) Resveratrol attenuates obesity-
associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 61:1444–1454.

Jeon BT, Jeong EA, Shin HJ, Lee Y, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS (2012b) Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 61:1444–1454.

Kanthasamy K, Gordon R, Jin H, Anantharam V, Ali S, Kanthasamy AG, Kanthasamy A (2011) Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apopotic cell death in a cell culture model of neurotoxicity. Curr Neuropharmacol 9:49–53.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.

Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF (2010) Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91:1590–1597.

Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S (2012) Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 73:1428–1433.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214–219.

Kirkpatrick B, Miller BJ (2013) Inflammation and schizophrenia. Schizophr Bull 39:1174–1179.

Mansur RB, Zugman A, Asevedo EM, da Cunha GR, Bressan RA, Brietzke E (2012) Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 66:247–260.

Meyer U, Schwarz MJ, Müller N (2011) Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132:96–110.

Millan MJ, Fone K, Steckler T, Horan WP (2014) Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24:645–692.

Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671.

Mitra S, Mahintamani T, Kavoor AR, Nizamie SH (2016) Negative symptoms in schizophrenia. Ind Psychiatry J 25:135–144.

Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T (2003) Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119:767–775.

Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L (2015) Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim Biophys Acta 1852:1202–1208.

Pineda-Ramírez N, Gutiérrez Aguilar GF, Espinoza-Rojo M, Aguilera P (2018) Current evidence for AMPK activation involvement on resveratrol-induced neuroprotection in cerebral ischemia. Nutr Neurosci 21:229–247.

Potvin S, Stip E, Sephyr AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808.

Quincozes-Santos A, Bobermin LD, Tramontina AC, Wachtchow KM, Tagliari B, Souza D, Wyse AT, Gonçalves CA (2014) Oxidative stress mediated by NMDA, AMPA/KA channels in acute hippocampal slices: neuroprotective effect of resveratrol. Toxicol in Vitro 28:544–551.

Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR (2014) Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 6:218.

Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST, Huggins KW, Broderick TL, Babu JR (2013) Resveratrol protects the brain of obese mice from oxidative damage. Oxid Med Cell Longev 2013:419092.

Remington G, Agid O, Foussias G (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother 11:589–607.

Rezaei F, et al. (2017) Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 32.

Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. Plos Med 2:e141.

Saiko P, Szakmary A, Jaeger W, Szeckers T (2008) Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658:68–94.

Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gouglol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S (2014) A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord 155:216–222.

Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382:27–32.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer’s Disease Cooperative Study (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85:1383–1391.

Uphegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108.

Witte AV, Kerti L, Margulies DS, Flöel A (2014) Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 34:7862–7870.

Zhang F, Wang YY, Liu H, Lu YF, Wu Q, Liu J, Shi JS (2012) Resveratrol produces neuroprotective effects on cultured dopaminergic neurons through prompting astroglial BDNF and GDNF release. Evid Based Complement Alternat Med 2012:937605.

Zortea K, Franco VC, Guimarães P, Belmonte-de-Abreu PS (2016) Resveratrol supplementation did not improve cognition in patients with schizophrenia: results from a randomized clinical trial. Front Psychiatry 7:159.